Aetna follows CMS lead in ESA restrictions
Executive Summary
Aetna has altered its coverage of erythropoiesis-stimulating agents in certain indications in the non-renal setting to mirror changes made by CMS in its final national coverage determination, issued July 30 (1"The Pink Sheet" Aug. 6, 2007, p. 21). Aetna describes the eight non-renal indications CMS considers not reasonable and necessary as "experimental and investigational." In its update, Aetna said the changes were "based upon guidelines" from CMS. The NCD itself has come under increased scrutiny as of late, with congressional action recently initiated that potentially render the NCD invalid (2"The Pink Sheet" Oct. 1, 2007, p. 16)...
You may also be interested in...
Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach
CMS has abandoned the idea of limiting some uses of erythropoiesis-stimulating agents to a research trial setting, despite receiving public comments that the "coverage with evidence development" approach may be acceptable in some circumstances
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.